Hepatitis C Donors and Outcomes in Kidney Transplantation
Mentor Information
Jacentha Buggs (Tampa General Procurement and Research) & Victor Bowers (Department of Surgery, Morsani College)
Description
The purpose of this study is to evaluate the safety and outcomes of transplanting kidneys from hepatitis C infected donors into non-infected recipients, specifically those donors with positive Nucleic Acid Testing (NAT+). We hypothesize that recipients who receive NAT+ kidneys have similar outcomes in graft function and graft survival when compared to those recipients who received non-hepatitis C kidneys. This is a single-center, retrospective cohort study of all adult kidney transplants performed at Tampa General Hospital from January 1, 2019, to April 30, 2020. We accessed 322 electronic health records. We excluded pediatric patients under 18-years of age as well as multi-organ recipients. Differences between the study and the control group for continuous variables were assessed using the independent sample t-test and the chi-squared test for binary variables. Of the 322 total patients analyzed, 21 recipients were in our study group, having received a NAT+ kidney as a non-infected recipient. The remaining 301 recipients were included in our control group, having received a NAT- kidney. Recipient outcomes were preserved between the two groups. In the study group, 3 (14.2%) patients experienced delayed graft function (DGF) while 63 (20.9%) patients in the control group had DGF. Seven (33.3%) recipients in the study group experienced postoperative complications, while 123 (40.8%) patients in the control group did. Overall, the results above demonstrate that our hypothesis is correct. It appears that non-infected patients receiving NAT+ kidneys have similar outcomes in graft function and survival when compared to those who received NAT- kidneys.
Hepatitis C Donors and Outcomes in Kidney Transplantation
The purpose of this study is to evaluate the safety and outcomes of transplanting kidneys from hepatitis C infected donors into non-infected recipients, specifically those donors with positive Nucleic Acid Testing (NAT+). We hypothesize that recipients who receive NAT+ kidneys have similar outcomes in graft function and graft survival when compared to those recipients who received non-hepatitis C kidneys. This is a single-center, retrospective cohort study of all adult kidney transplants performed at Tampa General Hospital from January 1, 2019, to April 30, 2020. We accessed 322 electronic health records. We excluded pediatric patients under 18-years of age as well as multi-organ recipients. Differences between the study and the control group for continuous variables were assessed using the independent sample t-test and the chi-squared test for binary variables. Of the 322 total patients analyzed, 21 recipients were in our study group, having received a NAT+ kidney as a non-infected recipient. The remaining 301 recipients were included in our control group, having received a NAT- kidney. Recipient outcomes were preserved between the two groups. In the study group, 3 (14.2%) patients experienced delayed graft function (DGF) while 63 (20.9%) patients in the control group had DGF. Seven (33.3%) recipients in the study group experienced postoperative complications, while 123 (40.8%) patients in the control group did. Overall, the results above demonstrate that our hypothesis is correct. It appears that non-infected patients receiving NAT+ kidneys have similar outcomes in graft function and survival when compared to those who received NAT- kidneys.
